FAST: a Phase III trial of an anti-CLDN18.2 antibody GEJ adenocarcinoma

Press brief by Salah-Eddin Al-Batran, MD of the Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

Share this video  
3rd June 2016